FP-01.1-Adjuvant + placebo

FP-01.1-Adjuvant + placebo is a combination used as a control arm in clinical trials evaluating the safety and immunogenicity of an adjuvanted formulation of the synthetic peptide-based influenza A vaccine, FP-01.1, compared to placebo[1][6]. FP-01.1 is a novel universal influenza A vaccine candidate composed of six fluorocarbon-modified 35-mer peptides that encapsulate multiple CD4+ and CD8+ T-cell epitopes from conserved regions of the influenza virus[2][7]. The adjuvanted formulation (FP-01.1-Adjuvant) is designed to enhance immune responses by including an immunostimulatory component (adjuvant), though specific details on the adjuvant are not provided in public sources[6]. The mechanism involves induction of robust anti-influenza T cell responses—both CD4+ and CD8+—across diverse HLA types, aiming for broad protection against divergent influenza strains[2][7]. Clinical studies have shown acceptable safety profiles and strong immunogenicity in healthy adults[2].